Model AUR200 - Recombinant Fc Protein Targeting BAFF/APRIL

AUR200 is a recombinant Fc fusion protein designed to specifically block B-cell Activating Factor, known as BAFF, and A Proliferation-Inducing Ligand, known as APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions. AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA in 2023.